Harnessing Large Language Models in oncology: ESMO’s framework for integration in the clinic
The ELCAP statements, developed by a group of international experts, help oncology stakeholders recognise the opportunities and the risks of these artificial intelligence systems by categorising them into three types
The long road toward treatment personalisation for pancreatic and rectal cancers
The 2025 ESMO Awardee, Thierry Conroy, traces the major advances in the field while noting that several barriers to improving patient outcomes remain
How will computational and AI tools guide future anticancer strategies?
Growing evidence shows that AI models can predict a patient's disease trajectory and signal the need for early therapeutic intervention
Mentoring is key to address the gender gap in oncology
Receiving the 2025 ESMO Women for Oncology Award, Dr Natasha Leighl stresses the importance of passing along learnings, support and opportunities to others
ESMO confers a new award on pioneer female oncologist in Ecuador
Glenda Ramos Martínez receives the ESMO Oncologist of the Year Award, launched this year by the Society
International collaboration and a shared vision are key to improving cancer patients’ lives
The 2025 ESMO Lifetime Achievement Awardee, Prof. Rolf Stahel, reflects on the role of the oncology community to drive progress in cancer care
How you can do your part in the AI transformation of oncology
An interview with ESMO President Prof. Fabrice André underscores the importance for any medical oncologist of developing artificial intelligence literacy
ESMO awards its first fellowship to support digital and computational pathology
The recipient, Balazs Acs from Karolinska Institutet, will conduct a two-year project to transform the manual aspects of breast cancer pathology into quantitative ones
Lamarca: “Understanding the problem is the first step to solving it”
Career growth is a step-by-step journey, built on resilience, clarity, and the ability to face challenges head-on - because success never happens overnight
The updated ESMO-MCBS captures the evolving treatment landscape and patient priorities
The ESMO-Magnitude of Clinical Benefit Scale has been enhanced to address critical aspects of modern oncology trials, such as novel study designs, quality of life and long-term survival benefits